Effectiveness and safety of oxycodone/naloxone in the management of chronic pain in patients with systemic sclerosis with recurrent digital ulcers: two case reports

Figures & data

Table 1 Assessment of pain and gastrointestinal symptoms using patient-reported outcomes during treatment with oral prolonged-release oxycodone/naloxone combination

	Case report 1		Case report 2
	Baseline	2 months later	Baseline	2 months later
Drug and dosage
OXN-PR daily dose (mg)	5/2.5 bid	5/2.5 bid	5/2.5 bid	5/2.5 bid
Pain assessment
Pain intensity, mean NRS score	5/10	3/10	8/10	4/10
BPI, severity	24/50	14/50	39/50	19/50
BPI, interference	40/50	22/50	34/50	27/50
GIT symptom assessment
UCLA-SCTC GIT 2.0 total score	0.58	0.43	0.06	0.83
UCLA-SCTC GIT 2.0 constipation score	1.0	0.5	0.0	0.0

Note: Bid means twice a day.

Abbreviations: BPI, Brief Pain Inventory; GIT, gastrointestinal tract; NRS, numeric rating scale; OXN, oxycodone/naloxone; PR, prolonged release; UCLA-SCTC GIT 2.0, UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract 2.0.

Figure 1 Digital ulcers of the third and fifth fingertips of the right hand (A) and the fourth fingertip of the left hand (C) at baseline. The underlying calcinosis is shown in the plain X-ray images of the right (B) and left (D) hands.